{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:37:00Z","timestamp":1789270620922,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.semarthrit.2024.152416","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T06:55:48Z","timestamp":1707980148000},"page":"152416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-1609","authenticated-orcid":false,"given":"Huan","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Shan","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2024.152416_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1315-z","article-title":"Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study","volume":"19","author":"Bengtsson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2024.152416_bib0002","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac210","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study","author":"Kerola","year":"2022","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152416_bib0003","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152416_bib0004","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","article-title":"Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis","volume":"77","author":"Crowson","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152416_bib0005","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/annrheumdis-2016-210275","article-title":"Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis","volume":"76","author":"Schieir","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152416_bib0006","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152416_bib0007","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152416_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20976975","article-title":"Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus","volume":"12","author":"Fragoulis","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152416_bib0009","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/acr.23567","article-title":"Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis","volume":"70","author":"Lauper","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152416_bib0010","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152416_bib0011","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.semarthrit.2018.03.005","article-title":"Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis","volume":"48","author":"Cooksey","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152416_bib0012","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/rheumatology\/kep366","article-title":"The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review","volume":"49","author":"Westlake","year":"2010","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152416_bib0013","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152416_bib0014","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti\u2013tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152416_bib0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152416_bib0016","article-title":"Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis","volume":"4","author":"Wong","year":"2022","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152416_bib0017","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-215312","article-title":"Demographics and medication use of patients with late-onset Alzheimer's disease in Hong Kong","volume":"87","author":"Wong","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.semarthrit.2024.152416_bib0018","series-title":"Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. seminars in arthritis and rheumatism","first-page":"367","author":"Cooksey","year":"2018"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152416_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277321","article-title":"Impact of early initiation of sodium-glucose cotransporter 2 inhibitor on cardiovascular outcomes in people with diabetes and known or at risk of atherosclerotic cardiovascular disease: propensity score matched analysis","volume":"17","author":"Sun","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152416_bib0021","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/01.CIR.0000055014.62083.05","article-title":"C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152416_bib0022","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"24","key":"10.1016\/j.semarthrit.2024.152416_bib0023","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","article-title":"Explaining how \u201chigh-grade\u201d systemic inflammation accelerates vascular risk in rheumatoid arthritis","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152416_bib0024","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41584-019-0243-5","article-title":"Systemic effects of IL-17 in inflammatory arthritis","volume":"15","author":"Beringer","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152416_bib0025","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/annrheumdis-2015-207980","article-title":"Incidence and predictors for cardiovascular events in patients with psoriatic arthritis","volume":"75","author":"Eder","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152416_bib0026","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/annrheumdis-2013-204715","article-title":"The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis","volume":"73","author":"Zhang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152416_bib0027","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/annrheumdis-2021-220125","article-title":"Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis","volume":"80","author":"Johnson","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152416_bib0028","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1002\/art.24040","article-title":"Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages","volume":"58","author":"Reiss","year":"2008","journal-title":"Arthritis & Rheumatism: Official Journal of the American College of Rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152416_bib0029","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/art.39039","article-title":"Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism","volume":"67","author":"Ronda","year":"2015","journal-title":"Arthritis & Rheumatology"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152416_bib0030","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152416_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-018-1669-x","article-title":"Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study","volume":"20","author":"Lee","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152416_bib0032","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.200265","article-title":"The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"48","author":"Ozen","year":"2021","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152416_bib0033","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3899\/jrheum.131464","article-title":"Tumor necrosis factor-\u03b1 inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study","volume":"41","author":"Desai","year":"2014","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152416_bib0034","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152416_bib0035","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152416_bib0036","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/rheumatology\/kem311","article-title":"Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis","volume":"47","author":"Panoulas","year":"2008","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152416_bib0037","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13075-016-1157-0","article-title":"Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis","volume":"18","author":"Verhoeven","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152416_bib0038","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-136-1-200201010-00013","article-title":"Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful?","volume":"136","year":"2002","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152416_bib0039","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"Del Rinc\u00f3n","year":"2014","journal-title":"Arthritis & rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152416_bib0040","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/acr.21899","article-title":"Decline of mean initial prednisone dosage from 10.3 to 3.6mg\/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5mg\/day","volume":"65","author":"Pincus","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152416_bib0041","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard-2023-224185","article-title":"Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study","volume":"82","author":"So","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152416_bib0042","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.4049\/jimmunol.167.5.2831","article-title":"Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2","volume":"167","author":"Caughey","year":"2001","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.semarthrit.2024.152416_bib0043","first-page":"342","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","author":"Trelle","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152416_bib0044","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/BOR.0000000000000881","article-title":"Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases","volume":"34","author":"So","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152416_bib0045","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152416_bib0046","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2012-203137","article-title":"Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study","volume":"73","author":"Lindhardsen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152416_bib0047","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2020-217595","article-title":"DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study","volume":"79","author":"Lam","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 51","key":"10.1016\/j.semarthrit.2024.152416_bib0048","first-page":"S35","article-title":"Mortality in rheumatoid arthritis: 2008 update","volume":"26","author":"Sokka","year":"2008","journal-title":"Clin Exp Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722400057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722400057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:15:50Z","timestamp":1758734150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722400057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":47,"alternative-id":["S004901722400057X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152416","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152416"}}